INVEX Therapeutics Ltd Asset Resilience Ratio
INVEX Therapeutics Ltd asset resilience ratio. INVEX Therapeutics Ltd (IXC) has an Asset Resilience Ratio of 61.52% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of INVEX Therapeutics Ltd to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of INVEX Therapeutics Ltd (2026–2026)
Asset resilience ratio of INVEX Therapeutics Ltd from 2026 to 2026. This chart shows how INVEX Therapeutics Ltd's Asset Resilience Ratio has changed over time. Read INVEX Therapeutics Ltd (IXC) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down INVEX Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see IXC total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$2.50 Million | 61.52% |
| Total Liquid Assets | AU$2.50 Million | 61.52% |
Asset Resilience Insights
- Very High Liquidity: INVEX Therapeutics Ltd maintains exceptional liquid asset reserves at 61.52% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
INVEX Therapeutics Ltd Industry Peers by Asset Resilience Ratio
Compare INVEX Therapeutics Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 1.69% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 38.51% |
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392 |
Biotechnology | 11.40% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Zealand Pharma A/S
CO:ZEAL |
Biotechnology | 63.98% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
INVEX Therapeutics Ltd Asset Resilience Ratio by Year (2026–2026)
INVEX Therapeutics Ltd asset resilience ratio by year from 2026 to 2026. The table below shows the annual Asset Resilience Ratio data for INVEX Therapeutics Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-06-30 | 61.52% | AU$2.50 Million ≈ $1.77 Million |
AU$4.06 Million ≈ $2.88 Million |
-- |
About INVEX Therapeutics Ltd
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of efficacious treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has comple… Read more